公开(公告)号：US20020081720A1

公开(公告)日：2002-06-27

申请号：US09871856

申请日：2001-05-31

Applicant: Immunex Corporation

Inventor： William C. Dougall ,  Dirk M. Anderson ,  Laurent Galibert ,  Eugene Maraskovsky

IPC: C07H021/04 ,  C12P021/06 ,  C12N015/09 ,  A61K039/395 ,  C12N015/00 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C12N005/00 ,  C12N005/02 ,  C12P021/08 ,  C07K001/00 ,  C07K014/00 ,  A61K038/24 ,  A61K038/27

CPC classification number: C07K16/241 ,  A61K38/00 ,  C07K14/435 ,  C07K14/52 ,  C07K14/525 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/7151 ,  C07K16/2875 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/73 ,  C12Q1/6876

Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.

Abstract translation: 公开了分离的受体，编码这些受体的DNA和由其制备的药物组合物。 分离的受体可用于调节免疫应答。 受体也可用于筛选其抑制剂。

公开(公告)号：US20020077458A1

公开(公告)日：2002-06-20

申请号：US09835788

申请日：2001-04-17

Inventor： Jian Ni ,  Steven M. Ruben

IPC: A01N037/18 ,  A61K038/00 ,  C12Q001/68 ,  G01N033/53 ,  C07H021/04 ,  A61K031/70 ,  A01N043/04 ,  C12P021/06 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  C12N005/00 ,  C12N005/02 ,  C07K001/00 ,  C07K014/00 ,  C12P021/08

CPC classification number: C07K14/70578 ,  A61K38/00

Abstract: The present invention relates to novel human DDCR polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human DDCR polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human DDCR polypeptides.

Abstract translation: 本发明涉及新型人DDCR多肽和含有编码这些多肽的基因的编码区的分离的核酸。 还提供了用于产生人DDCR多肽的载体，宿主细胞，抗体和重组方法。 本发明还涉及用于诊断和治疗与这些新型人DDCR多肽相关的疾病的诊断和治疗方法。

公开(公告)号：US20020077281A1

公开(公告)日：2002-06-20

申请号：US09146802

申请日：1998-09-03

Inventor： BRIAN HENRY VICKERY

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/23 ,  A61K038/12

CPC classification number: C07K14/635 ,  A61K38/29

Abstract: This invention provides methods of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, wherein amino acid residues 22-31 form an amphipathic null-helix. Systemic administration is a preferred mode of delivery.

Abstract translation: 本发明提供了骨愈合和骨折修复的方法，包括向有需要的患者施用有效量的甲状旁腺激素相关肽（PTHrP）及其盐的多肽类似物，其中氨基酸残基22-31形成两亲性α-螺旋 。 系统管理是优选的交付方式。

公开(公告)号：US20020065405A1

公开(公告)日：2002-05-30

申请号：US09761288

申请日：2001-01-16

Inventor： Muralidhara Padigaru ,  Sudhirdas Prayaga ,  Raymond J. Taupier JR. ,  Vishnu Mishra ,  Velizar Tchernev ,  Kimberly Spytek ,  Li Li

IPC: C07H021/02 ,  C07H021/04 ,  A61K039/00 ,  A61K039/38 ,  C07K002/00 ,  C07K004/00 ,  C07K016/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K017/00 ,  A61K038/00 ,  C07K001/00

CPC classification number: C07K14/705

Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

公开(公告)号：US20020064533A1

公开(公告)日：2002-05-30

申请号：US09873459

申请日：2001-06-04

Inventor： Kenneth Murray

IPC: C07K005/00 ,  A61K038/04 ,  A61K039/112 ,  C07K007/00 ,  A61K039/165 ,  A61K039/275 ,  A61K039/29 ,  A61K039/08 ,  A61K039/002 ,  C07K017/00 ,  A61K039/12 ,  A61K039/04 ,  C07K016/00

CPC classification number: A61K39/385 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/5258 ,  A61K2039/6075 ,  A61K2039/627 ,  A61K2039/64 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/70 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  G01N33/56983 ,  G01N2333/02 ,  G01N2469/20 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/396 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/472 ,  Y02A50/484 ,  Y02A50/52 ,  Y02A50/53 ,  Y02A50/54 ,  Y02A50/58 ,  Y02A50/59 ,  Y02A50/60 ,  Y10S530/806 ,  Y10S530/81

Abstract: This invention relates to hepatitis B virus (nullHBVnull) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.

Abstract translation: 本发明涉及以多种免疫原特异性为特征的乙型肝炎病毒（“HBV”）核心抗原颗粒。 更具体地，本发明涉及包含免疫原，表位或其它相关结构的HBV核心抗原颗粒，其通过配体选择性地结合HBV核心蛋白的配体进行交联。 这样的颗粒可以用作各种免疫原性表位的递送系统，包括HBV衣壳结合肽，其有利地还通过阻断HBV核心蛋白和HBV表面蛋白之间的相互作用来抑制和干扰HBV病毒装配。 不同免疫原和/或衣壳结合肽配体的混合物可以交联到相同的HBV核心颗粒。 这样得到的多组分或多价HBV核心颗粒可以有利地用于治疗和预防性疫苗和组合物，以及使用它们的诊断组合物和方法中。

公开(公告)号：US20020061552A1

公开(公告)日：2002-05-23

申请号：US09730989

申请日：2000-12-05

Inventor： Dong Yan ,  Lewis T. Williams

IPC: A61K038/00 ,  C07H021/04 ,  C12P021/06 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/04 ,  C07K001/00 ,  C07K014/00 ,  C12N015/85 ,  C12N015/87

CPC classification number: C07K14/47

Abstract: Two novel proteins that interact with mammalian Dishevelled protein, and the corresponding polynucleotide sequences encoding the proteins, are disclosed. The proteins are referred to as mNkd and DAP 1A. mNkd is expressed at a higher level in mammalian lung tissues than in other mammalian tissues. mNkd inhibits Wnt signaling, and is an activator of the JNK pathway.

Abstract translation: 公开了与哺乳动物紊乱蛋白质相互作用的两种新蛋白质和编码蛋白质的相应多核苷酸序列。 蛋白质称为mNkd和DAP 1A。 mNkd在哺乳动物肺组织中表达高于其他哺乳动物组织。 mNkd抑制Wnt信号，并且是JNK途径的激活剂。

公开(公告)号：US20020058609A1

公开(公告)日：2002-05-16

申请号：US09261473

申请日：1999-02-26

Inventor： ELI GILBOA ,  SMITA K. NAIR ,  CHRISTOPHER V. NICCHITTA

IPC: A01N037/18 ,  A61K038/00 ,  A61K039/00 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  C07K001/00

CPC classification number: A61K39/385 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/53 ,  A61K2039/6043 ,  A61K2039/622 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/466 ,  Y02A50/478

Abstract: A method of eliciting an immune response in a vertebrate subject. The method includes the administration to a vertebrate subject of a composition including an amount of a purified complex including calreticulin bound to an antigenic molecule to elicit an immune response to the antigenic molecule in the vertebrate subject. Therapeutic methods, compositions and kits are also disclosed wherein the elicited immune response is utilized as a treatment for cancer and for infectious diseases.

Abstract translation: 在脊椎动物受试者中引发免疫应答的方法。 该方法包括向脊椎动物受试者施用包含一定量的纯化复合物的组合物，所述组合物包括与抗原分子结合的钙网蛋白，以引起对脊椎动物受试者中的抗原性分子的免疫应答。 还公开了治疗方法，组合物和试剂盒，其中引发的免疫应答用作癌症和感染性疾病的治疗。

公开(公告)号：US20020055627A1

公开(公告)日：2002-05-09

申请号：US09925299

申请日：2001-08-10

Inventor： Craig A. Rosen ,  Steven M. Ruben

IPC: A01N037/18 ,  A61K038/00 ,  G01N033/53 ,  G01N033/567 ,  C07H021/04 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  C12N005/00 ,  C12N005/02 ,  C12P021/08

CPC classification number: C07K14/4703 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/4702 ,  C07K14/4748 ,  C07K2319/00 ,  C12N2799/026

Abstract: The present invention relates to novel colorectal cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as nullcolorectal cancer antigens,null and antibodies that immunospecifically bind these polypeptides, and the use of such colorectal cancer polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the colon and/or rectum, including, but not limited to, the presence of colorectal cancer and colorectal cancer metastases. More specifically, isolated colorectal cancer nucleic acid molecules are provided encoding novel colorectal cancer polypeptides. Novel colorectal cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colorectal cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon and/or rectum, including colorectal cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

Abstract translation: 本发明涉及新型结肠直肠癌相关多核苷酸，由这些多核苷酸编码的多肽本文共同称为“结肠直肠癌抗原”，以及免疫特异性结合这些多肽的抗体，以及使用这种结肠直肠癌多核苷酸，抗原和抗体 检测，治疗，预防和/或预后结肠和/或直肠疾病，包括但不限于结肠直肠癌和结肠直肠癌转移的存在。 更具体地，提供编码新型结肠直肠癌多肽的分离的结肠直肠癌核酸分子。 提供结合这些多肽的新型结肠直肠癌多肽和抗体。 还提供载体，宿主细胞，以及用于产生人结肠直肠癌多核苷酸，多肽和/或抗体的重组和合成方法。 本发明还涉及用于诊断，治疗，预防和/或预后与结肠和/或直肠相关的疾病（包括结肠直肠癌）和治疗这些疾病的治疗方法的诊断和治疗方法。 本发明还涉及用于鉴定本发明的多核苷酸和多肽的激动剂和拮抗剂的筛选方法。 本发明还涉及用于抑制或促进本发明多肽的产生和/或功能的方法和/或组合物。

公开(公告)号：US20020042374A1

公开(公告)日：2002-04-11

申请号：US09076948

申请日：1998-05-13

Inventor： MICHAEL ANTHONY CAWTHORNE ,  YONG-LING LIU ,  MATTHEW V. SENNITT

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/12

CPC classification number: C07K14/6555 ,  A61K38/31

Abstract: The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.

Abstract translation: 本发明涉及治疗患者的胰岛素抵抗或综合征X的方法。 该方法包括向所述患者施用治疗有效量的生长抑素或生长抑素激动剂的步骤。

公开(公告)号：US20020039999A1

公开(公告)日：2002-04-04

申请号：US09798114

申请日：2001-03-01

Inventor： Alan M. Ezrin ,  Dominique P. Bridon ,  Darren L. Holmes ,  Peter G. Milner

IPC: A61K038/04 ,  C07K017/00 ,  C07K016/00 ,  C07K007/00 ,  C07K005/00 ,  A61K038/16 ,  A61K035/14 ,  C07K014/00 ,  C07K001/00 ,  A61K038/00

CPC classification number: C07K14/70 ,  A61K38/00 ,  A61K47/64 ,  C07K14/665 ,  C07K2319/00

Abstract: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system

Abstract translation: 通过将所述抗伤害感受剂与提供能够与血液成分（优选血液）反应的功能反应性基团的材料组合，由抗伤害感受剂，特别是阿片样物质或阿片样物质类似物，更具体地说是强啡肽，内啡肽，delphphins，脑啡肽或其类似物制备缀合物 细胞或蛋白质）。 所述缀合物允许延长抗伤害感受剂的治疗寿命。 可以向患者施用以缓解疼痛，产生镇痛作用或辅助麻醉药物撤出的情况，也可用作受体活性的探针。 对患者的施用可以在体内或体外制备，并且可以通过将包含反应性官能团的衍生物引入患者的血管系统或者在外部（或体外）中制备这种缀合物并将该缀合物引入到 患者血管系统